Rationale And Objectives: Large hepatocellular carcinoma (HCC) exhibits heterogeneous morphologies and varied responses to treatment. We evaluated outcomes of patients with different large HCC classifications receiving surgical resection (SR) or transarterial chemoembolization plus ablation (TA).
Materials And Methods: Patients with HCC ≥ 5 cm receiving SR or TA between May 2016 and December 2020 at one center were analyzed retrospectively and with propensity score matching (PSM). Overall survival (OS) and progression-free survival (PFS) of the 2 treatment groups were compared. Tumors were classified according to imaging morphology and gross pathology: Type I, simple nodular; Type II, simple nodular with extranodular growth or confluent multinodular; Type III, infiltrative.
Results: Of 644 patients, 374 met the inclusion criteria (300 received SR and 74 received TA). Before PSM, median follow-up was 51.2 (IQR 29.6-65.3) months, and the SR group had longer OS (HR 2.13, 95% CI 1.44-3.15, p<0.001) and PFS (HR 2.31, 95% CI 1.66-3.20, p<0.001) than the TA group; after PSM these differences were not significant (all p>0.05). Infiltrative HCC (Type III) was an independent negative prognostic factor for OS and PFS. Within both treatment groups, patients with infiltrative HCC had shorter OS and PFS than patients with non-infiltrative HCC (Types I and II) (all p<0.001).
Conclusion: For patients with HCC ≥ 5 cm, tumor classification is an important prognostic factor. In patients with non-infiltrative HCC, TA and SR had comparable OS after PSM. For patients with infiltrative HCC, TA and SR had limited efficacy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.acra.2025.02.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hepatic Dearterialization for Nonresectable Liver Tumors in Five Dogs and Two Cats.
J Vet Intern Med
March 2025
Cornell University College of Veterinary Medicine, Ithaca, New York, USA.
Introduction: Some massive or nodular liver tumors can make surgical resection dangerous. Transarterial embolization and chemoembolization recently have been evaluated in dogs and cats, but multinodular or diffuse tumors make selective embolization difficult, impractical, and may require multiple anesthetic events. Hepatic dearterialization in humans has been shown to be safe and sometimes successful in promoting temporary tumor regression.
View Article and Find Full Text PDFQuantitative Magnetic Resonance Imaging Methods for the Assessment and Prediction of Treatment Response to Transarterial Chemoembolization in Hepatocellular Carcinoma.
Acad Radiol
March 2025
Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China. Electronic address:
This article reviews the state-of-the-art applications of quantitative magnetic resonance imaging (qMRI) in predicting and evaluating response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). HCC is a highly heterogeneous tumor, and its response to TACE varies significantly among patients. Early identification of treatment response is critical for optimizing management.
View Article and Find Full Text PDFGamma-glutamyl transferase-to-lymphocyte ratio as a prognostic marker in patients with hepatocellular carcinoma undergoing hepatectomy.
World J Gastrointest Surg
February 2025
Department of General Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330008, Jiangxi Province, China.
Background: We investigated the utility of gamma-glutamyl transferase-to-lymphocyte ratio (GLR) as a predictive indicator for postoperative survival in patients with hepatocellular carcinoma (HCC) across different time periods and developed a predictive model based on this.
Aim: To evaluate the prognostic accuracy of GLR for overall survival (OS) in patients with HCC and its impact over time.
Methods: This study enrolled 301 patients with HCC treated with curative hepatectomy.
Prognostic Value of Changes in Combined Child-Pugh Class and ALBI Grade in Hepatocellular Carcinoma Treated with Transcatheter Intra-Arterial Therapy Plus Targeted Therapy and PD-(L)1 Inhibitors.
J Hepatocell Carcinoma
March 2025
Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
Purpose: This study aims to investigate liver function changes in hepatocellular carcinoma (HCC) patients treated with transcatheter intra-arterial therapy plus molecular targeted agents and programmed cell death-1 (ligand-1) inhibitors, and evaluate the prognostic significance of the combination of Child-Pugh (CP) class and albumin-bilirubin (ALBI) grade (CP/ALBI).
Methods: This is a retrospective study. A total of 149 patients from 2019 to 2023 in China were included.
Survival Benefits of Transarterial Chemoembolization Plus Ablation Therapy in Patients With Intermediate or Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
Cancer Manag Res
March 2025
Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Purpose: To evaluate the survival outcomes of patients with intermediate to advanced hepatocellular carcinoma (HCC), patients who underwent transarterial chemoembolization (TACE) alone were compared with those who underwent a combination of TACE and ablation therapy.
Patients And Methods: This study retrospectively evaluated 536 HCC patients in our hospital from July 2016 to November 2022. All patients underwent TACE, with a subset also receiving ablation therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!